Factor Xa Inhibitor Plus P2Y12 Inhibitor OK in ACS

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Pairing rivaroxaban (Xarelto) with a P2Y12 inhibitor in the post-acute coronary syndromes (ACS) setting led to a similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor, researchers reported here. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings